Navigation Links
PharmaVentures Helps Secure Investor for Former MSD Research Site
Date:1/19/2012

OXFORD, England, January 19, 2012 /PRNewswire/ --

PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.

The deal follows exceptional collaborative working between MSD, the Scottish Life Sciences community and the Scottish Government.

The transfer of this research facility from MSD to BioCity Scotland unlocks over 130,000 sq ft of purpose-built laboratories and offices on the 23 acre site capable of supporting drug discovery and development for growing bioscience, pharmaceutical, med-tech and healthcare companies.  

Fintan Walton, Chief Executive of PharmaVentures, said: "PharmaVentures is delighted to have worked with MSD in finding a new investor like BioCity Scotland to turn the former MSD research facility into an incubator for growing innovative enterprises. This is a fantastic outcome for the site and for the UK Life Science industry as a whole, creating new job opportunities from start-up companies and providing the infrastructure to support expansion of existing businesses."

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures:

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of their track record of successful outcomes, resulting from their unique insight into the world of deal making, their internationally recognised analytical and valuation capabilities, their own proprietary deal making database PharmaDeals®  (http://www.pharmadeals.net), containing over 42,000 deal records, and their extensive business relationship network and our outstanding success in M&A transactions.

Over the years PharmaVentures has built considerable experience in the M&A field including the divestment of manufacturing and R&D businesses most of which have led to both the protection and the creation of jobs.

Their services cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (in and out-licensing)
  • M&A (companies & assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:

Dr Fintan Walton, Chief Executive, PharmaVentures
+44(0)1865-332-700
fintan.walton@pharmaventures.com



'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
3. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
4. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
5. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
8. Software Helps Research Facilities Meet New NIH Financial Conflict of Interest (FCOI) Requirements
9. FindTheBest Helps Parents Find Cord Blood Banks
10. Mirage-effect helps researchers hide objects
11. The Vitality Group Helps U.S. Businesses Navigate New Legal Environment for Health and Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):